About HEARTCARE-B Company

Shanghai Xinwei Medical Technology Co., Ltd. (stock code: 06609.HK) was founded in 2016. The company is committed to improving the accessibility of innovative medical technology and protecting life and health. In six years, Xinwei Medical pioneered the first one-stop solution for stroke treatment and prevention in the field of neurological intervention in China. It has a full product pipeline from acute ischemic stroke and neurovascular stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment to interventional pathway devices. It has applied for more than 200 patents, and its sales channels cover all provinces in China except Hong Kong, Macau, and Taiwan. Based on its current leading edge, Xinwei Medical will continue to focus on popularizing emerging medical procedures, focusing on the unmet needs of clinicians and patients in mainland China, and operating various emerging business segments including neurological intervention, whole-hearted treatment, pulmonary intervention, and computer-aided technology. We look forward to continuing to launch innovative interventional devices defining emerging procedures in these medical fields with huge potential to reduce mortality from major diseases and improve patient prognosis.